Status: Recruiting
Treatment of Immune-related Adverse Events Refractory to Standard Therapy and Associated Changes in Immunophenotype
This study is an open, monocentric study. It includes patients with irAE refractory to standard therapy or patients where corticosteroids cannot be tapered. Patients will either be treated with ECP or second line immunosuppressive therapy according to investigator's choice. Patients will be followed for 24 weeks after first treatment.
Participants needed: 50
Trial details
Biological sex: AllType: ObservationalSponsor: Lucie HeinzerlingUpdated: Mar 15, 2024Locations: 1
Eligibility criteria
Subjects must we willing and able to comply with scheduled visits and must have... [+2]
Contraindications for the treatment with ECP including a known sensitivity to ps... [+2]